The application of compound16, on the other hand, demonstrates promising therapeutic effects in PBRM1-dependent prostate cancer, suggesting its potential as a foundational treatment for PBRM1-driven cancers.749 As for the other molecules, though their binding ability and inhibitory effects have been validated at the molecular level, sufficient evidence is still lacking in vivo or in vitro to demonstrate their clinical value. Here, PBRM1 is linked to prostate cancer.